1. Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?

   • William David Strain
   • Matthias Blüher
   • Païvi Paldánius

   Commentary Open access 12 August 2014 Pages: 347 - 354

2. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

   • Sanjay Kalra

   Review Open access 26 November 2014 Pages: 355 - 366

3. The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist

   • Stephen C. Bain

   Review Open access 16 July 2014 Pages: 367 - 383

   

4. A Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes

   • George Dailey
   • Edward Wang

   Review Open access 17 December 2014 Pages: 385 - 402

   

5. A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus

   • Nozomi Domeki
   • Mihoko Matsumura
   • Yoshimasa Aso

   Original Research Open access 27 August 2014 Pages: 403 - 413

   

6. Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

   • Kohei Kaku
   • Hiroshi Maegawa
   • Anna Maria Langkilde

   Original Research Open access 24 October 2014 Pages: 415 - 433

   

7. Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials

   • Jiten Vora
   • Torsten Christensen
   • Steve C. Bain

   Original Research Open access 01 August 2014 Pages: 435 - 446

8. Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes

   • Seamus Sreenan
   • Marc Andersen
   • Marc Evans

   Original Research Open access 15 July 2014 Pages: 447 - 458

   

9. Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

   • Bo Ahrén
   • James Edward Foley
   • Anja Schweizer

   Original Research Open access 18 September 2014 Pages: 459 - 469

   

10. Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data

    • Sarah Bujac
    • Angelo Del Parigi
    • Anne-Marie Boothman

    Original Research Open access 12 December 2014 Pages: 471 - 482

    

11. Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data

    • Zdravko Kamenov

    Original Research Open access 23 September 2014 Pages: 483 - 498

    

12. Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries

    • Victoria Divino
    • Mitch DeKoven
    • Matthew Reaney

    Original Research Open access 04 November 2014 Pages: 499 - 520

    

13. A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes

    • Morgan Bron
    • Craig Wilson
    • Penny Fleck

    Original Research Open access 26 November 2014 Pages: 521 - 534

    

14. Role of Comorbidities as Limiting Factors to the Effect of Hyperbaric Oxygen in Diabetic Foot Patients: A Retrospective Analysis

    • Esra A. Akgül
    • Jale Karakaya
    • Salih Aydın

    Original Research Open access 02 October 2014 Pages: 535 - 544

    

15. Initial Experience and Evaluation of Reusable Insulin Pen Devices Among Patients with Diabetes in Emerging Countries

    • Balduino Tschiedel
    • Oscar Almeida
    • Frank Flacke

    Original Research Open access 12 September 2014 Pages: 545 - 555

    

16. Improving Self-Monitoring of Blood Glucose among Adults with Type 1 Diabetes: Results of the Mobile™ Study

    • Jane Overland
    • Jessie Abousleiman
    • Christopher Gilfillan

    Original Research Open access 11 December 2014 Pages: 557 - 565

17. Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK

    • Hayley Bennett
    • Phil McEwan
    • Jason Gordon

    Original Research Open access 04 September 2014 Pages: 567 - 578

    

18. Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States

    • Qian Li
    • Abhishek Chitnis
    • Jakob Langer

    Original Research Open access 26 September 2014 Pages: 579 - 590

    

19. Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden

    • Aliasghar A. Kiadaliri
    • Ulf G. Gerdtham
    • Katarina Steen Carlsson

    Original Research Open access 12 September 2014 Pages: 591 - 607

    

20. Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study

    • Borje Darpo
    • Meijian Zhou
    • Rickey R. Reinhardt

    Erratum Open access 18 July 2014 Pages: 609 - 609